Immutep Ltd. IMMP 深 沪
等待开盘 11-04 09:30:00 美东时间
1.83
-0.060
-3.17%
华盛通- 最 高1.8945
- 今 开1.89
- 成交量 11.08万股
- 最 低 1.80
- 昨 收 1.89
- 总市值 2.69亿
- 52周最高 2.71
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 1.32
- 委 比 27.27%
- 总股本 1.47亿
- 历史最高 7.95
- 量 比 0.77
- 振 幅 5.00%
- 历史最低 0.53
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immutep Secures A$4.6 Million R&D Tax Incentive from French Government
Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Limited has received a ...
11-03 08:08
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
<b>Immutep Announces Promising Results for Efti Combination in NSCLC</b> <br>Immutep's INSIGHT-003 trial shows that combining eftilagimod alfa (efti) with KEYTRUDA and chemotherapy achieved strong response rates (ORR) across all PD-L1 expression levels in first-line non-small cell lung cancer (1L NSCLC). Notably, the ORR was 61.7% in patients with low or no PD-L1 expression (TPS <50%), significantly outperforming historical controls (40.8%). The ...
10-20 12:00
Immutep’s Efti Shows Promising Results in Lung Cancer Treatment
Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep Limited has ann...
10-20 05:37
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Immutep Limited has received positive feedback from the FDA confirming 30mg of eftilagimod alfa (efti) as the optimal biological dose for its oncology pipeline and future Biological License Applications (BLA). The registrational TACTI-004 (KEYNOTE-F91) Phase III trial for first-line non-small cell lung cancer (NSCLC) is now opening clinical sites in the United States. This trial evaluates efti combined with MSD’s KEYTRUDA and chemotherapy for adv...
10-13 12:00
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy
An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limite...
10-13 06:18
Immutep Announces Its Global Phase III TACTI-004 Trial For Advanced Non-Small Cell Lung Cancer Has Surpassed Key Milestone With Over 170 Patients Enrolled And Randomized
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across 24 countries now
10-09 20:07
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
Immutep’s TACTI-004 Phase III trial for eftilagimod alfa in advanced NSCLC has enrolled over 170 patients, surpassing the threshold for futility analysis. Over 100 sites across 24 countries are activated. The futility analysis is on track for Q1 2026. Previous studies showed promising efficacy of efti combined with KEYTRUDA, addressing high unmet need in NSCLC.
10-09 12:00
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
Immutep Limited has initiated a Phase II trial evaluating neoadjuvant eftilagimod alfa (efti) as monotherapy and in combination with chemotherapy in HR+/HER2-negative breast cancer patients. The study, led by GW Cancer Center, aims to assess pathological complete response rates and will enroll up to 50 patients. Efti, a novel immunotherapy, activates a broad anti-cancer immune response and has shown promise in earlier-stage disease. Immutep provi...
09-22 12:00
Immutep Collaborates with GW Cancer Center on Efti Trial for Breast Cancer
The latest announcement is out from Immutep Ltd ( ($AU:IMM) ). Immutep Limited ...
09-22 07:47
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
The outlook for the KAT6 inhibitors market is strengthening as interest in epig...
09-17 05:31
